GlassScriptPhysician profile
Samuel C Hall
NPI 1487115838
$6,320.22
in general payments reported to CMS, 2019-2025
54 companies · $2,709 in 2025
The $2,709 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.16 · 2021: $212 · 2022: $420 · 2023: $1,280 · 2024: $1,681 · 2025: $2,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,201 · Education: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,200.66 |
| Education | $469.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $498.32 | 2023-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $437.03 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $346.19 | 2021-2022 | |
| Celgene Corporation | $306.46 | 2024-2025 | Reblozyl |
| Eisai INC. | $294.13 | 2023-2025 | |
| Lilly USA, LLC | $255.31 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $254.73 | 2021-2025 | Opdivo |
| Incyte Corporation | $248.11 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Daiichi Sankyo INC. | $222.92 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $221.31 | 2024-2025 | Erleada, Balversa, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $217.91 | 2021-2025 | Imfinzi, Enhertu |
| Seagen INC. | $199.98 | 2023-2025 | |
| Pfizer INC. | $196.71 | 2021-2025 | |
| Exelixis INC. | $193.37 | 2023-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $192.98 | 2023-2025 | Keytruda, Welireg, Lynparza |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $155.46 | 2023-2025 | Ojjaara, Jemperli, Blenrep |
| Astellas Pharma US INC | $147.14 | 2024-2025 | Vyloy, Xtandi |
| Janssen Scientific Affairs, LLC | $141.44 | 2023-2025 | Tecvayli, Rybrevant, Talvey |
| Genzyme Corporation | $136.18 | 2023-2025 | |
| Tersera Therapeutics LLC | $133.02 | 2023-2025 | Zoladex, Quzyttir, Xermelo |
| Takeda Pharmaceuticals U.S.A., INC. | $122.63 | 2023-2025 | Iclusig, Alunbrig, Fruzaqla |
| Genentech USA, INC. | $102.35 | 2023-2025 | Polivy, Phesgo, Lunsumio |
| Sobi, INC | $91.63 | 2023-2025 | |
| Pharmaessentia USA Corporation | $90.81 | 2023-2025 | Besremi |
| Actelion Pharmaceuticals US, INC. | $87.18 | 2022-2023 | Uptravi |
| Aurinia Pharma U.S., INC. | $76.92 | 2022 | |
| Pharmacosmos Therapeutics INC. | $76.88 | 2023-2025 | Monoferric, Cosela |
| Blueprint Medicines Corporation | $65.06 | 2023-2024 | Ayvakit |
| Genmab U.S., INC. | $63.53 | 2023-2025 | Epkinly |
| Beigene USA, INC. | $61.32 | 2024-2025 | Brukinsa, Tevimbra |
| Sumitomo Pharma America, INC. | $61.18 | 2024 | Orgovyx |
| Emd Serono, INC. | $60.77 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $47.47 | 2023-2024 | Rezlidhia, Tavalisse |
| Array Biopharma INC | $46.07 | 2025 | Braftovi, Mektovi, Tukysa |
| Beone Medicines USA, INC. | $43.63 | 2025 | Brukinsa |
| Servier Pharmaceuticals LLC | $34.06 | 2025 | |
| Alexion Pharmaceuticals, INC. | $31.62 | 2020-2023 | Ultomiris |
| Taiho Oncology, INC. | $30.93 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.01 | 2023 | |
| Puma Biotechnology, INC. | $29.87 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $28.84 | 2023 | Xpovio |
| Abbvie INC. | $28.28 | 2024 | |
| Syndax Pharmaceuticals, INC. | $25.10 | 2025 | |
| Sanofi-Aventis U.S. LLC | $25.06 | 2024 | |
| Xeris Pharmaceuticals, INC. | $22.51 | 2022 | |
| Mallinckrodt Hospital Products INC. | $21.82 | 2025 | Terlivaz |
| Cti Biopharma Corp. | $21.32 | 2023 | Vonjo |
| Gilead Sciences, INC. | $16.07 | 2021 | |
| Dexcom, INC. | $15.95 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $14.45 | 2025 | Sancuso |
| Myriad Genetic Laboratories, INC. | $14.42 | 2025 | Myrisk |
| Lifescan, INC. | $13.95 | 2022 | |
| Veracyte, INC. | $12.24 | 2023 | |
| Pharmaand Gmbh | $7.59 | 2024 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.